Singular Genomics Announces Pricing of Upsized Initial Public Offering
Gunderson Dettmer advised client Singular Genomics Systems, Inc. (“Singular Genomics”) in its initial public offering. The company focuses on delivering genomic technologies for the advancement of science and medicine and has announced the pricing of its upsized initial public offering of 11,730,000 shares at a price of $22.00 per share for a total of approximately $258.1 million in aggregate gross proceeds.
The San Diego-based sequencing technology firm added nearly 2 million more shares to the offering that started trading on the Nasdaq on May 27, 2021 under the ticker symbol "OMIC."
J.P. Morgan, Goldman Sachs & Co. LLC, BofA Securities and Cowen acted as lead book-running managers for the offering. UBS Investment Bank also acted as a book-running manager.
The Gunderson deal team was led by partners Ryan Gunderson and Heather Aune, and associates Michael Deitch, Jessie Yu and Riley Millender.